Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy

Mou,Wenjun; Xue,Hui; Tong,Hongli; Sun,Shengjie; Zhang,Zhuhong; Zhang,Chunyan; Sun,Qiyu; Dong,Jing; Wen,Xinyu; Yan,Guangtao; Tian,Yaping

doi:10.3892/ol.2014.1988

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy

Authors:
- Wenjun Mou
- Hui Xue
- Hongli Tong
- Shengjie Sun
- Zhuhong Zhang
- Chunyan Zhang
- Qiyu Sun
- Jing Dong
- Xinyu Wen
- Guangtao Yan
- Yaping Tian
View Affiliations

Affiliations: School of Medicine, Nankai University, Tianjin 300071, P.R. China, Research Laboratory of Biochemistry, Basic Medical Institute, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China, Oncology Department, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: March 21, 2014 https://doi.org/10.3892/ol.2014.1988
Pages: 2073-2078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin/pemetrexed chemotherapy has been established as a standard treatment in lung adenocarcinoma. However, the response to the cisplatin/pemetrexed combination varies considerably among patients due to individual variations. Thus, novel biomarkers are required to aid the prediction of the response to the cisplatin/pemetrexed combination. We hypothesized that leptin expression may be a determinant for prognosis in lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Serum from consenting patients with lung adenocarcinoma were obtained for the measurement of leptin and associated tumor biomarkers. Leptin expression was measured by radioimmunoassay. Carcinoembryonic antigen (CEA), carbohydrate antigen 19‑9 (CA19‑9), CA15‑3, CA125, CA72‑4, cytokeratin 19 fragment (CYFRA21‑1) and neuron‑specific enolase (NSE) expression were determined by electrochemiluminescence immunoassays. Serum squamous cell carcinoma antigen levels were measured using a microparticle enzyme immunoassay. The associations between serum leptin and tumor biomarker expression were evaluated by Spearman's correlation analysis. Serum CEA, CA19‑9, CA15‑3, CA125, CA72‑4, CYFRA21‑1 and NSE levels showed no obvious difference among patients. However, a trend towards an improved prognosis was observed in patients with lower serum leptin at diagnosis and an increase during cisplatin/pemetrexed chemotherapy. The results indicated that the serum leptin level has prognostic indications in patients with advanced lung adenocarcinoma during cisplatin/pemetrexed chemotherapy, which indicates that it may be a useful marker for the prognosis of cancer patients undergoing chemotherapy treatment.

View Figures

View References

1	Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl 8): S4–S66. 2001.PubMed/NCBI
2	Okada M: Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis. Thorac Surg Clin. 23:179–186. 2013. View Article : Google Scholar : PubMed/NCBI
3	Raparia K, Villa C, DeCamp MM, Patel JD and Mehta MP: Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Arch Pathol Lab Med. 137:481–491. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nuijten MJ, Aultman R, de Carpeño JC, et al: An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Curr Med Res Opin. 27:2193–2201. 2011. View Article : Google Scholar : PubMed/NCBI
5	Dinglin XX, Huang Y, Liu H, et al: Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol. 112:461–466. 2013. View Article : Google Scholar : PubMed/NCBI
6	Tímár J: Role of contemporary pathological diagnostics in the personalized treatment of cancer. Magy Onkol. 57:26–32. 2013.(In Hungarian).
7	Park SY, Lee JG, Kim J, et al: Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 79:156–160. 2013. View Article : Google Scholar : PubMed/NCBI
8	Ono A, Takahashi T, Mori K, et al: Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 13:3542013. View Article : Google Scholar : PubMed/NCBI
9	Takeuchi S, Nonaka M, Kadokura M and Takaba T: Prognostic significance of serum squamous cell carcinoma antigen in surgically treated lung cancer. Ann Thorac Cardiovasc Surg. 9:98–104. 2003.PubMed/NCBI
10	Hatzakis KD, Froudarakis ME, Bouros D, et al: Prognostic value of serum tumor markers in patients with lung cancer. Respiration. 69:25–29. 2002. View Article : Google Scholar : PubMed/NCBI
11	Bréchot JM, Chevret S, Nataf J, et al: Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 33:385–391. 1997.PubMed/NCBI
12	Rubins JB, Dunitz J, Rubins HB, et al: Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg. 116:412–416. 1998. View Article : Google Scholar : PubMed/NCBI
13	Seregni E, Foa P, Bogni A, et al: Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC). Oncol Rep. 3:95–101. 1996.PubMed/NCBI
14	Diez M, Torres A, Pollán M, et al: Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer. 73:1368–1376. 1994. View Article : Google Scholar : PubMed/NCBI
15	Riesener KP and Schumpelick V: Ultrasound diagnosis in abdominal trauma - how much experience does the surgeon need to perform ultrasonic diagnosis? Langenbecks Arch Chir. 377:205–206. 1992.(In German).
16	Cristofori R, Aimo G, Mengozzi G, et al: Tumor markers kinetic in malignant lung neoplasms. J Cardiovasc Surg (Torino). 40:299–305. 1999.PubMed/NCBI
17	Yoshimasu T, Miyoshi S, Maebeya S, et al: Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma. Cancer. 79:1533–1540. 1997. View Article : Google Scholar : PubMed/NCBI
18	Cammisotto PG, Bukowiecki LJ, Deshaies Y and Bendayan M: Leptin biosynthetic pathway in white adipocytes. Biochem Cell Biol. 84:207–214. 2006. View Article : Google Scholar : PubMed/NCBI
19	Tas F, Duranyildiz D, Argon A, et al: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 22:353–358. 2005. View Article : Google Scholar : PubMed/NCBI
20	Ribeiro R, Araujo A, Lopes C and Medeiros R: Immunoinflammatory mechanisms in lung cancer development: is leptin a mediator? J Thorac Oncol. 2:105–108. 2007.PubMed/NCBI
21	Karapanagiotou EM, Tsochatzis EA, Dilana KD, et al: The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 61:391–397. 2008. View Article : Google Scholar : PubMed/NCBI
22	Zhao X, Huang K, Zhu Z, Chen S and Hu R: Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol. 22:1317–1321. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wang SN, Yeh YT, Yang SF, Chai CY and Lee KT: Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol. 59:930–934. 2006. View Article : Google Scholar : PubMed/NCBI
24	Guadagni F, Roselli M, Martini F, et al: Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 29:3321–3327. 2009.PubMed/NCBI
25	Sato Y, Watanabe H, Sone M, et al; Japan Intervention Radiology in Oncology Study Group-JIVROSG. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 118:16–22. 2013. View Article : Google Scholar
26	Lin J, Gao XN, Yan GT, et al: Endogenous leptin fluctuates in hepatic ischemia/reperfusion injury and represents a potential therapeutic target. World J Gastroenterol. 16:5424–5434. 2010. View Article : Google Scholar : PubMed/NCBI
27	Fleeman N, Bagust A, McLeod C, et al: Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess. 14(Suppl 1): 47–53. 2010.
28	Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
29	Besse B, Olaussen KA and Soria JC: ERCC1 and RRM1: ready for prime time? J Clin Oncol. 31:1050–1060. 2013. View Article : Google Scholar : PubMed/NCBI
30	Pillai RN, Brodie SA, Sica GL, et al: CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res. 19:1603–1611. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kerenidi T, Lada M, Tsaroucha A, et al: Clinical significance of serum adipokines levels in lung cancer. Med Oncol. 30:5072013. View Article : Google Scholar : PubMed/NCBI